Ionis Pharmaceuticals Inc. (IONS)
IONS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/874015/000087401526000115/0000874015-26-000115-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IONS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000874015 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | CA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $943.7M |
| Net income | -$381.4M |
| Operating income | -$381.7M |
| Net margin | -40.4% |
| Operating margin | -40.4% |
| Revenue growth | +33.8% |
| Cash | $372.3M |
| Total assets | $3.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $296.3M cash; operating cash flow -$136.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 166,545,100 (2026-11-03); 161,974,393 a year earlier; 143,472,119 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.1M, sold $145.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $242.7M | -$110.0M | -$179.4M | $296.3M | $0 | $960.1M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $267.9M | -$114.6M | $565.5M | $350.1M | $0 | $874.1M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $246.1M | -$92.5M | -$792.8M | $173.4M | $432.5M | $1.1B | 10-Q 2026-04-29 |
| Q4 2025 2025-12-31 | $203.3M | -$229.4M | -$137.7M | $372.3M | $1.8B | $943.7M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $156.7M | -$128.6M | -$131.4M | $338.3M | $630.9M | $967.0M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $452.0M | $123.6M | $151.3M | $297.3M | $630.1M | $944.1M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $131.6M | -$146.9M | -$150.8M | $264.2M | No debt tags | $717.3M | 10-Q 2026-04-29 |
| Q4 2024 2024-12-31 | $226.6M | -$104.3M | -$116.1M | $242.1M | $1.3B | $705.1M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-09-10 |
| Latest annual report IONIS PHARMACEUTICALS, INC. 10-K 12-31-2025 | 10-K | 2026-02-26 |
| Latest quarterly / interim QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 1,008 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -26.3% |
| 1 month | -31.4% |
| 3 months | -48.0% |
| Year to date | -63.3% |
| 1 year | -58.4% |
| From 52-week high | -66.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
| EWTX | Edgewise Therapeutics Inc. | $43.68 | -4.90% | $4.8B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| TNGX | Tango Therapeutics Inc. | $24.17 | -5.22% | $4.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier